<DOC>
	<DOCNO>NCT01156922</DOCNO>
	<brief_summary>Based pilot patient observation , experience prior study KTS-1-2008 , investigator anticipate severely affected chronic fatigue syndrome patient may benefit B-cell depletion therapy use Rituximab induction maintenance treatment . The hypothesis least subset chronic fatigue syndrome ( CFS ) patient activate immune system involve B-lymphocytes , prolong B-cell depletion may alleviate symptom . An approved amendment ( April 15th 2011 ) : study extend 5 patient . For 5 patient study , standard plasma exchange may perform 2-3 week prior start B-lymphocyte depletion use Rituximab ( protocol ) . Approved amendment ( December 2011 ) : patient gradual improvement CFS/ME symptoms 12 month follow-up , reach clear response , 6 additional Rituximab infusion ( 500 mg/m2 , max 1000 mg ) may give follow 12 month period .</brief_summary>
	<brief_title>B-cell Depletion Using Monoclonal Anti-CD20 Antibody Rituximab Very Severe Chronic Fatigue Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Encephalomyelitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>patient severely affect chronic fatigue syndrome , WHO performance status III IV . age 1866 year informed consent patient fatigue , fulfil criterion CFS pregnancy lactation previous malignant disease except basal cell carcinoma skin cervical carcinoma situ previous major immunological disease , except autoimmune disease diabetes mellitus thyroiditis endogenous depression lack ability comply protocol multiallergy risk serious drug reaction reduce renal function ( creatinin &gt; 1.5 x upper normal limit [ UNL ] ) reduce liver function ( bilirubin transaminase &gt; 1.5 x UNL ) HIV positivity evidence clinically significant infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic fatigue syndrome</keyword>
	<keyword>CFS</keyword>
	<keyword>Myalgic encephalomyelitis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B-cell depletion</keyword>
</DOC>